Compare CIF & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CIF | HBIO |
|---|---|---|
| Founded | 1988 | 1901 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.8M | 26.5M |
| IPO Year | N/A | 2000 |
| Metric | CIF | HBIO |
|---|---|---|
| Price | $1.60 | $6.08 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | ★ 55.1K | 22.0K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 10.11% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $116,176,000.00 |
| Revenue This Year | N/A | $4.77 |
| Revenue Next Year | N/A | $8.55 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.57 | $0.38 |
| 52 Week High | $1.82 | $7.50 |
| Indicator | CIF | HBIO |
|---|---|---|
| Relative Strength Index (RSI) | 44.10 | 52.30 |
| Support Level | $1.58 | $6.05 |
| Resistance Level | $1.73 | $6.79 |
| Average True Range (ATR) | 0.02 | 0.37 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 40.00 | 38.37 |
Mfs Intermediate High Income Fund is a United States-based diversified closed-end management investment company. Its investment objective is to seek high current income, but it may also consider capital appreciation. The fund invests a majority of its net assets, including borrowings for investment purposes, in high-income debt instruments. Its portfolio of investments includes investment-grade corporate bonds, government securities and other securities. The portfolio includes Midstream, Financial Institutions, Energy, Cable TV, and Utilities.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.